ARQ-154-127 is a Phase 1, open-label, single arm, maximum usage pharmacokinetic and safety study of roflumilast foam 0.3% in participants with scalp and body psoriasis.
The goal of the study is to:
* Evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile of ARQ-154 foam 0.3%.
* Assess the safety and tolerability of ARQ-154 foam 0.3%
Accelerate enrollment with targeted advertising campaigns
Step 1: Add a recruitment campaign (optional)
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites
Your plan includes posting your clinical trials on our recruitment portal and mobile apps. Boost your trials with targeted advertising campaigns to reach more participants, faster.
What you get with a targeted campaign
We handle everything: audience targeting, creative development, geo targeting to your site locations, and ongoing optimizations. Qualified participant inquiries flow directly into your dashboard. Inquiries typically begin within a few days and continue throughout the campaign.
Select your study's therapeutic area and indication below. This helps us calculate accurate campaign budget and delivery timelines based on recruitment complexity.
Maximum participant inquiries available for this indication.
Cost per Inquiry
—
Total Campaign Investment
—
Estimated Campaign Duration
—
Timeline varies based on campaign performance and audience targeting.
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites